EGFR-IN-8
CAS No. 2407957-87-1
EGFR-IN-8( —— )
Catalog No. M26192 CAS No. 2407957-87-1
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 259 | Get Quote |
|
10MG | 430 | Get Quote |
|
25MG | 710 | Get Quote |
|
50MG | 972 | Get Quote |
|
100MG | 1332 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEGFR-IN-8
-
NoteResearch use only, not for human use.
-
Brief DescriptionEGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
-
DescriptionEGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.(In Vitro):In A549, PC9, H1975, CL68, and CL97?cells, EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. EGFR-IN-8 (0-20 μM; 24, 48, 72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97?cells at different time intervals, with IC50 values ranging from 0.3 to 0.6?μM and 0.2-0.5?μM after 48 and 72?h of treatment respectively.(In Vivo):EGFR-IN-8 (50,150?mg/kg; oral gavage) exhibits suppression (29% and 60%, respectively) of H1975 xenograft tumor growth in a dose-dependent manner.
-
In VitroEGFR-IN-8 (0-20 μM; 24-72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97?cells at different time intervals, with IC50 values ranging from 0.3 to 0.6?μM and 0.2-0.5?μM after 48 and 72?h of treatment respectively. EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. Cell Viability Assay Cell Line:A549, PC9, H1975, CL68, and CL97?cells Concentration:0-20 μM Incubation Time:24 hours, 48 hours, 72 hours Result:Showed inhibitory effects on different cells.Western Blot Analysis Cell Line:A549, PC9, H1975, CL68, and CL97?cells Concentration:0-0.6 μM Incubation Time:48 hours Result:Decreased EGFR and c-Met expression.
-
In VivoEGFR-IN-8 (oral gavage; 50 and 150?mg/kg; once daily; 20 days) exhibits a dose-dependent suppression (29% and 60%, respectively) of H1975 xenograft tumor growth at 50 and 150?mg/kg. Animal Model:Nude mice H1975 xenograft tumor model Dosage:50 and 150?mg/kg Administration:Oral gavage; 50 and 150?mg/kg; once daily; 20 days Result:Inhibited H1975 xenograft tumor growth.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2407957-87-1
-
Formula Weight662.03
-
Molecular FormulaC32H23ClF3N7O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 8.33 mg/mL (12.58 mM)
-
SMILESFC(F)(F)c1cc(NC(=O)Nc2cccc(c2)-c2nc(no2)-c2ccc(NC(=O)c3cccnc3)cc2Cl)ccc1NC(=O)C1CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chandoga J, et al. Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways. Biochem Pharmacol. 1994 Feb 9;47(3):515-9.
molnova catalog
related products
-
WHI-P258
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3.
-
AEE-788
A potent, orally bioavailable dual EGFR/VEGFR receptor tyrosine kinase inhibitor with IC50 of 2, 6, 77 and 59 nM for EGFR, ErbB2, KDR and Flt-1, respectively.
-
Alflutinib methanesu...
Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.